VivoSeq
Oncology

Thymoma

26

Pipeline Programs↗

6

Active Trials↗

14

Companies Involved↗

Thymoma is an emerging landscape with 26 programs across 14 companies. The most active players are Merck & Co., Novartis, Pfizer. 4 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

78/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Novartis logo

Novartis

4 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2K

Karyopharm Therapeutics Inc

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

22 of 27 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody311%Peptide27%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 27 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Recruiting4 · 25%
Terminated2 · 13%
Unknown status1 · 6%
Not yet recruiting1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Recruiting·SSun Yat-sen University·Phase 2·NCT06730308·45 enrolled
Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06924619·178 enrolled
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03295227·37 enrolled
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Recruiting·National Cancer Institute (NCI)·N/A·NCT01950572·1,000 enrolled
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03076554·56 enrolled
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
Not yet recruiting·—·Phase 2·NCT05816694·50 enrolled
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Completed·PProf. Dr. Berthold Schalke·Phase 2·NCT02021942·16 enrolled
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Completed·PPatrick Joseph Loehrer Sr.·Phase 2·NCT02220855·14 enrolled
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Completed·Novartis logoNovartis·Phase 2·NCT00332969·25 enrolled
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003283·38 enrolled
Preoperative Treatment of Patients With High Risk Thymoma
Completed·—·Phase 2·NCT00387868·21 enrolled
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00010257·46 enrolled
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
Completed·IIndiana University School of Medicine·Phase 2·NCT00369889·18 enrolled
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Terminated·National Cancer Institute (NCI)·Phase 2·NCT00718809·21 enrolled
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Terminated·TTiziana Life Sciences LTD·Phase 2·NCT01301391·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)